ERBB2 and triple-negative breast carcinoma: In line with our study, a large cohort study conducted by Peiffer et al. with a longer median follow-up time of 54 months identified substantial improvement in OS favoring HER2-low patients for stages II to IV triple-negative breast cancer and stages III to IV hormone receptor-positive/HER2-negative disease when analyzed by hormone receptor status and clinical stage [27].